

17101416D

SENATE BILL NO. 1220

Offered January 11, 2017

Prefiled January 10, 2017

A BILL to amend and reenact §§ 54.1-3303 and 54.1-3423 of the Code of Virginia, relating to practice of telemedicine; prescribing.

Patron—Barker

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3303 and 54.1-3423 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic purposes only.

A. A prescription for a controlled substance may be issued only by a practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled substances, or by a licensed nurse practitioner pursuant to § 54.1-2957.01, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32. The prescription shall be issued for a medicinal or therapeutic purpose and may be issued only to persons or animals with whom the practitioner has a bona fide practitioner-patient relationship.

For purposes of this section, a bona fide practitioner-patient-pharmacist relationship is one in which a practitioner prescribes, and a pharmacist dispenses, controlled substances in good faith to his patient for a medicinal or therapeutic purpose within the course of his professional practice. In addition, a bona fide practitioner-patient relationship means that the practitioner shall (i) ensure that a medical or drug history is obtained; (ii) provide information to the patient about the benefits and risks of the drug being prescribed; (iii) perform or have performed an appropriate examination of the patient, either physically or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically; except for medical emergencies, the examination of the patient shall have been performed by the practitioner himself, within the group in which he practices, or by a consulting practitioner prior to issuing a prescription; and (iv) initiate additional interventions and follow-up care, if necessary, especially if a prescribed drug may have serious side effects. *A practitioner who performs or has performed an appropriate examination of the patient required pursuant to clause (iii), either physically or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically, for the purpose of establishing a bona fide practitioner-patient relationship, may prescribe Schedule II through VI controlled substances to the patient, provided that the prescribing of such Schedule II through V controlled substance is in compliance with federal requirements for the practice of telemedicine.*

For the purpose of prescribing a Schedule VI controlled substance to a patient via telemedicine services as defined in § 38.2-3418.16, a prescriber may establish a bona fide practitioner-patient relationship by an examination through face-to-face interactive, two-way, real-time communications services or store-and-forward technologies when all of the following conditions are met: (a) the patient has provided a medical history that is available for review by the prescriber; (b) the prescriber obtains an updated medical history at the time of prescribing; (c) the prescriber makes a diagnosis at the time of prescribing; (d) the prescriber conforms to the standard of care expected of in-person care as appropriate to the patient's age and presenting condition, including when the standard of care requires the use of diagnostic testing and performance of a physical examination, which may be carried out through the use of peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the Commonwealth and authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or carrier, the prescriber has been credentialed by the health plan or carrier as a participating provider and the diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier pursuant to § 38.2-3418.16; and (g) upon request, the prescriber provides patient records in a timely manner in accordance with the provisions of § 32.1-127.1:03 and all other state and federal laws and regulations. Nothing in this paragraph shall permit a prescriber to establish a bona fide practitioner-patient relationship for the purpose of prescribing a Schedule VI controlled substance when the standard of care dictates that an in-person physical examination is necessary for diagnosis. Nothing in this paragraph shall apply to: (1) a prescriber providing on-call coverage per an agreement with another prescriber or his prescriber's professional entity or employer; (2) a prescriber consulting with another prescriber regarding a patient's care; or (3) orders of prescribers for hospital out-patients or in-patients.

INTRODUCED

SB1220

59 Any practitioner who prescribes any controlled substance with the knowledge that the controlled
60 substance will be used otherwise than medicinally or for therapeutic purposes shall be subject to the
61 criminal penalties provided in § 18.2-248 for violations of the provisions of law relating to the
62 distribution or possession of controlled substances.

63 B. In order to determine whether a prescription that appears questionable to the pharmacist results
64 from a bona fide practitioner-patient relationship, the pharmacist shall contact the prescribing practitioner
65 or his agent and verify the identity of the patient and name and quantity of the drug prescribed. The
66 person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in
67 § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of
68 controlled substances.

69 No prescription shall be filled unless there is a bona fide practitioner-patient-pharmacist relationship.
70 A prescription not issued in the usual course of treatment or for authorized research is not a valid
71 prescription.

72 C. Notwithstanding any provision of law to the contrary and consistent with recommendations of the
73 Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe
74 Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient
75 when (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as
76 defined in subsection A, with the diagnosed patient; (ii) in the practitioner's professional judgment, the
77 practitioner deems there is urgency to begin treatment to prevent the transmission of a communicable
78 disease; (iii) the practitioner has met all requirements of a bona fide practitioner-patient relationship, as
79 defined in subsection A, for the close contact except for the physical examination required in clause (iii)
80 of subsection A; and (iv) when such emergency treatment is necessary to prevent imminent risk of
81 death, life-threatening illness, or serious disability.

82 D. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state
83 practitioner of medicine, osteopathy, podiatry, dentistry or veterinary medicine authorized to issue such
84 prescription if the prescription complies with the requirements of this chapter and the Drug Control Act
85 (§ 54.1-3400 et seq.).

86 E. A licensed nurse practitioner who is authorized to prescribe controlled substances pursuant to
87 § 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for controlled
88 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
89 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

90 F. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to
91 § 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled
92 substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his
93 patient for a medicinal or therapeutic purpose within the scope of his professional practice.

94 G. A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to
95 Article 5 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide
96 manufacturers' professional samples to his patients for medicinal or therapeutic purposes within the
97 scope of his professional practice for the drugs specified on the TPA-Formulary, established pursuant to
98 § 54.1-3223, which shall be limited to (i) analgesics included on Schedule II controlled substances as
99 defined in § 54.1-3448 of the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in
100 combination with acetaminophen; (ii) oral analgesics included in Schedules III through VI, as defined in
101 §§ 54.1-3450 and 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.), which are appropriate to
102 relieve ocular pain; (iii) other oral Schedule VI controlled substances, as defined in § 54.1-3455 of the
103 Drug Control Act, appropriate to treat diseases and abnormal conditions of the human eye and its
104 adnexa; (iv) topically applied Schedule VI drugs, as defined in § 54.1-3455 of the Drug Control Act;
105 and (v) intramuscular administration of epinephrine for treatment of emergency cases of anaphylactic
106 shock.

107 H. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by
108 a member or committee of a hospital's medical staff when approving a standing order or protocol for the
109 administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with
110 § 32.1-126.4.

111 **§ 54.1-3423. Board to issue registration unless inconsistent with public interest; authorization to**
112 **conduct research; application and fees.**

113 A. The Board shall register an applicant to manufacture or distribute controlled substances included
114 in Schedules I through V unless it determines that the issuance of that registration would be inconsistent
115 with the public interest. In determining the public interest, the Board shall consider the following
116 factors:

- 117 1. Maintenance of effective controls against diversion of controlled substances into other than
118 legitimate medical, scientific, or industrial channels;
- 119 2. Compliance with applicable state and local law;
- 120 3. Any convictions of the applicant under any federal and state laws relating to any controlled

substance;

4. Past experience in the manufacture or distribution of controlled substances, and the existence in the applicant's establishment of effective controls against diversion;

5. Furnishing by the applicant of false or fraudulent material in any application filed under this chapter;

6. Suspension or revocation of the applicant's federal registration to manufacture, distribute, or dispense controlled substances as authorized by federal law; and

7. Any other factors relevant to and consistent with the public health and safety.

B. Registration under subsection A does not entitle a registrant to manufacture and distribute controlled substances in Schedule I or II other than those specified in the registration.

C. Practitioners must be registered to conduct research with controlled substances in Schedules II through VI. Practitioners registered under federal law to conduct research with Schedule I substances may conduct research with Schedule I substances within this Commonwealth upon furnishing the evidence of that federal registration.

D. The Board may register other persons or entities to possess controlled substances listed on Schedules II through VI upon a determination that (i) there is a documented need, (ii) the issuance of the registration is consistent with the public interest, (iii) the possession and subsequent use of the controlled substances complies with applicable state and federal laws and regulations, and (iv) the subsequent storage, use, and recordkeeping of the controlled substances will be under the general supervision of a licensed pharmacist, practitioner of medicine, osteopathy, podiatry, dentistry, *optometry*, or veterinary medicine, *licensed nurse practitioner*, or *licensed physician assistant* as specified in the Board's regulations. The Board shall consider, at a minimum, the factors listed in subsection A of this section in determining whether the registration shall be issued. Notwithstanding the exceptions listed in § 54.1-3422 A, the Board may mandate a controlled substances registration for sites maintaining certain types and quantities of Schedules II through VI controlled substances as it may specify in its regulations. The Board shall promulgate regulations related to requirements or criteria for the issuance of such controlled substances registration, storage, security, supervision, and recordkeeping.

E. The Board may register a public or private animal shelter as defined in § 3.2-6500 to purchase, possess, and administer certain Schedule II-VI controlled substances approved by the State Veterinarian for the purpose of euthanizing injured, sick, homeless, and unwanted domestic pets and animals; and to purchase, possess, and administer certain Schedule VI controlled substances for the purpose of preventing, controlling, and treating certain communicable diseases that failure to control would result in transmission to the animal population in the shelter. The drugs used for euthanasia shall be administered only in accordance with protocols established by the State Veterinarian and only by persons trained in accordance with instructions by the State Veterinarian. The list of Schedule VI drugs used for treatment and prevention of communicable diseases within the shelter shall be determined by the supervising veterinarian of the shelter and the drugs shall be administered only pursuant to written protocols established or approved by the supervising veterinarian of the shelter and only by persons who have been trained in accordance with instructions established or approved by the supervising veterinarian. The shelter shall maintain a copy of the approved list of drugs, written protocols for

administering, and training records of those persons administering drugs on the premises of the shelter.

F. The Board may register a crisis stabilization unit established pursuant to § 37.2-500 or 37.2-601 and licensed by the Department of Behavioral Health and Developmental Services to maintain a stock of Schedule VI controlled substances necessary for immediate treatment of patients admitted to the crisis stabilization unit, which may be accessed and administered by a nurse pursuant to a written or oral order of a prescriber in the absence of a prescriber. Schedule II through Schedule V controlled substances shall only be maintained if so authorized by federal law and Board regulations.

G. *The Board may register an entity at which a patient is treated by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically for the purpose of establishing a bona fide practitioner-patient relationship and is prescribed Schedule II through VI controlled substances to possess and administer Schedule II through VI controlled substances when such prescribing is in compliance with federal requirements for the practice of telemedicine and the patient is not in the physical presence of a practitioner registered with the U.S. Drug Enforcement Administration. In determining whether the registration shall be issued, the Board shall consider (i) the factors listed in subsection A, (ii) whether there is a documented need for such registration, and (iii) whether the issuance of the registration is consistent with the public interest.*

H. Applications for controlled substances registration certificates and renewals thereof shall be made on a form prescribed by the Board and such applications shall be accompanied by a fee in an amount to be determined by the Board.

I. Upon (i) any change in ownership or control of a business, (ii) any change of location of the

182 controlled substances stock, (iii) the termination of authority by or of the person named as the
183 responsible party on a controlled substances registration, or (iv) a change in the supervising practitioner,
184 if applicable, the registrant or responsible party shall immediately surrender the registration. The
185 registrant shall, within 14 days following surrender of a registration, file a new application and, if
186 applicable, name the new responsible party or supervising practitioner.
187 **2. That an emergency exists and this act is in force from its passage.**
188 **3. That the Board of Pharmacy shall promulgate regulations to implement the provisions of this**
189 **act to be effective within 280 days of its enactment.**